You are here

Imprimis to Offer Compounded Alternative to Restasis

Announcement follows judge’s ruling to toss patents

Days after a federal judge threw out patents on the dry-eye medicine Restasis (Allergan), a San Diego pharmaceutical company said it would offer a cheaper compounded version of cyclosporine. Shares of Imprimis Pharmaceuticals nearly doubled after the announcement.

Allergan last month sued Imprimis alleging the company is illegally manufacturing and selling unapproved new drugs. Imprimis called the lawsuit frivolous and a tactic to snuff out competition offering lower cost options to expensive drugs, Reuters reported.

The Imprimis product will cost 99 cents for a month’s supply and refills start at $79 a month.

Allergan recently stirred controversy after striking a deal with a Native American tribe that would shield certain patents on Restasis, which can cost $5,000 a year according to Imprimis. A U.S. judge Monday invalidated those patents on Restasis on the grounds that they cover ideas that are obvious.

Imprimis  said its compounded cyclosporine-based formulations are made from FDA-approved drug components and compounded in FDA-inspected facilities, require a patient-specific prescription, and may be customized according to patients' individual needs.

Topical cyclosporine, which is an off-patent and inexpensive drug, can cost more than $5,000 per year when purchased in the commercially available form of Restasis, Imprimis said. 

Sources: Reuters; October 19, 2017; Imprimis; October 19, 2017.

More Headlines

In study, progression-free survival was superior to Rituxan-based therapy
This is the first new medicine for this population in two decades
First agency-approved treatment for pediatric and adult patients with MPS VII
FDA clears NSS-2 Bridge in an effort to reduce symptoms
FDA establishes a pathway to speed approval for similar tests
Acorda Therapeutics hits pause on trial enrollment for tozadenant
New indication marks first adjuvant treatment after nephrectomy
First respiratory biologic with an eight-week maintenance dosing schedule
Under guidelines, nearly half of U.S. population will be diagnosed with hypertension